Veritable’s Intellia Therapeutics NTLA Stock Holding History

Veritable’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,046	Closed	-$275K	–	841
2020 Q4	$275K	Buy	+5,046	New	+$183K	0.01%	657

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Veritable's NTLA Position: Q1 2021 in Review

Veritable sold out of Intellia Therapeutics (NTLA) in Q1 2021, closing a stake of 5,046 shares — an estimated $275K sold.

Veritable first reported a position in NTLA in Q4 2020 and held it in 1 quarter. The position peaked at $275K in Q4 2020. 260 funds tracked by Wall St. Rank hold NTLA as of Q1 2021.

Veritable reported no remaining Intellia Therapeutics position as of Q1 2021 after selling out during the quarter.
Veritable sold 5,046 Intellia Therapeutics shares in Q1 2021, an estimated $275K.
Veritable first reported a position in Intellia Therapeutics in Q4 2020 and held it in 1 quarter.
Veritable's Intellia Therapeutics position peaked at $275K in Q4 2020.
260 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2021.

Based on Veritable's 13F filing for Q1 2021, filed 17 May 2021.